Medical Stocks To Consider – August 18th

UnitedHealth Group, Eli Lilly and Company, Novo Nordisk A/S, Soligenix, Tempus AI, Walmart, and AbbVie are the seven Medical stocks to watch today, according to MarketBeat’s stock screener tool. Medical stocks are shares of publicly traded companies involved in the healthcare sector—ranging from pharmaceutical and biotechnology firms to medical-device manufacturers and healthcare service providers. Investing in medical stocks lets shareholders participate in the development, approval and distribution of new therapies, diagnostics and treatments while seeking returns linked to the sector’s growth and innovation. These companies had the highest dollar trading volume of any Medical stocks within the last several days.

UnitedHealth Group (UNH)

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage, and health and well-being services to individuals age 50 and older addressing their needs; Medicaid plans, children's health insurance and health care programs; and health and dental benefits, and hospital and clinical services, as well as health care benefits products and services to state programs caring for the economically disadvantaged, medically underserved, and those without the benefit of employer-funded health care coverage.

UNH traded up $9.57 during trading on Monday, reaching $313.58. 28,548,534 shares of the stock were exchanged, compared to its average volume of 12,694,966. The stock has a market cap of $284.00 billion, a P/E ratio of 13.59, a price-to-earnings-growth ratio of 1.96 and a beta of 0.43. UnitedHealth Group has a twelve month low of $234.60 and a twelve month high of $630.73. The stock’s 50 day moving average price is $288.91 and its two-hundred day moving average price is $395.81. The company has a debt-to-equity ratio of 0.73, a quick ratio of 0.85 and a current ratio of 0.85.

Eli Lilly and Company (LLY)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Shares of NYSE:LLY traded down $1.05 on Monday, hitting $700.19. The company had a trading volume of 2,910,673 shares, compared to its average volume of 4,155,411. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $972.53. The stock has a market cap of $662.69 billion, a price-to-earnings ratio of 45.76, a P/E/G ratio of 0.98 and a beta of 0.44. The stock has a 50 day moving average price of $764.55 and a 200 day moving average price of $794.43. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86.

Novo Nordisk A/S (NVO)

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

Shares of Novo Nordisk A/S stock traded up $2.48 during trading on Monday, reaching $54.31. The company’s stock had a trading volume of 24,572,042 shares, compared to its average volume of 11,549,651. The business’s 50-day moving average price is $64.96 and its 200-day moving average price is $70.24. The firm has a market cap of $242.49 billion, a PE ratio of 14.92, a P/E/G ratio of 1.80 and a beta of 0.63. Novo Nordisk A/S has a 52 week low of $45.05 and a 52 week high of $139.74. The company has a quick ratio of 0.56, a current ratio of 0.78 and a debt-to-equity ratio of 0.52.

Soligenix (SNGX)

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease.

Shares of Soligenix stock traded up $2.24 during trading on Monday, reaching $5.02. The company’s stock had a trading volume of 154,330,388 shares, compared to its average volume of 4,250,727. The business’s 50-day moving average price is $1.79 and its 200-day moving average price is $2.01. The firm has a market cap of $16.37 million, a PE ratio of -1.32 and a beta of 1.95. Soligenix has a 52 week low of $1.09 and a 52 week high of $6.23.

Tempus AI (TEM)

Tempus AI Inc. is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.

TEM traded up $3.02 on Monday, hitting $76.80. 10,053,191 shares of the stock were exchanged, compared to its average volume of 12,539,568. Tempus AI has a 12 month low of $31.36 and a 12 month high of $91.45. The business has a 50-day moving average of $63.13 and a two-hundred day moving average of $58.64. The company has a debt-to-equity ratio of 2.58, a current ratio of 1.54 and a quick ratio of 1.43. The firm has a market capitalization of $13.34 billion, a price-to-earnings ratio of -64.59 and a beta of 4.98.

Walmart (WMT)

Walmart Inc. engages in the operation of retail, wholesale, other units, and eCommerce worldwide. The company operates through three segments: Walmart U.S., Walmart International, and Sam's Club. It operates supercenters, supermarkets, hypermarkets, warehouse clubs, cash and carry stores, and discount stores under Walmart and Walmart Neighborhood Market brands; membership-only warehouse clubs; ecommerce websites, such as walmart.com.mx, walmart.ca, flipkart.com, PhonePe and other sites; and mobile commerce applications.

NYSE WMT traded up $0.49 during trading on Monday, hitting $100.49. 5,989,441 shares of the company’s stock were exchanged, compared to its average volume of 18,873,721. The company has a current ratio of 0.78, a quick ratio of 0.22 and a debt-to-equity ratio of 0.47. The company has a market cap of $801.92 billion, a PE ratio of 42.94, a P/E/G ratio of 4.80 and a beta of 0.66. Walmart has a fifty-two week low of $73.34 and a fifty-two week high of $105.30. The stock’s 50 day moving average price is $97.60 and its two-hundred day moving average price is $95.56.

AbbVie (ABBV)

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.

Shares of AbbVie stock traded down $0.35 on Monday, hitting $206.34. The stock had a trading volume of 2,825,888 shares, compared to its average volume of 6,683,463. The stock has a 50 day moving average of $191.08 and a 200 day moving average of $192.31. AbbVie has a twelve month low of $163.81 and a twelve month high of $218.66. The company has a debt-to-equity ratio of 44.14, a quick ratio of 0.61 and a current ratio of 0.74. The firm has a market capitalization of $364.51 billion, a P/E ratio of 98.26, a PEG ratio of 1.33 and a beta of 0.50.